SCHEMBL2740952

SCHEMBL2740952

Cc1ncc(CO)c(/C=N/Nc2ccc([N+](=O)[O-])cc2S(=O)(=O)Nc2ccccc2Cl)c1O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 10/20 0.51
▸ GAA P10253 6/20 0.51
▸ ALDH1A1 P00352 6/20 0.51
▸ KDM4E B2RXH2 5/20 0.51
▸ TDP1 Q9NUW8 3/20 0.51
▸ TNNI3 P19429 1/20 0.49
▸ TNNT2 P45379 1/20 0.49
▸ TNNC1 P63316 1/20 0.49
▸ MEN1 O00255 9/20 0.48
▸ KMT2A Q03164 9/20 0.48
▸ HTT P42858 7/20 0.48
▸ SMN1; SMN2 Q16637 4/20 0.48
▸ RAB9A P51151 4/20 0.48
▸ NPC1 O15118 3/20 0.48
▸ PSMD14 O00487 2/20 0.48
▸ NPSR1 Q6W5P4 2/20 0.48
▸ L3MBTL1 Q9Y468 6/20 0.47
▸ ALPL P05186 1/20 0.47
▸ ALPI P09923 1/20 0.47
▸ ALPG P10696 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2741015 0.94 MEN1 (0.49) MAPTGAAALDH1A1KDM4ETDP1
SCHEMBL2740990 0.78 L3MBTL1 (0.57) MAPTGAAALDH1A1KDM4ETNNI3
SCHEMBL2740951 0.78 MEN1 (0.57) MAPTGAAALDH1A1KDM4ETDP1
SCHEMBL2740987 0.77 MEN1 (0.55) MAPTGAAALDH1A1KDM4ETDP1
SCHEMBL2740989 0.77 MEN1 (0.52) MAPTGAAALDH1A1TDP1TNNI3
SCHEMBL2741007 0.77 MEN1 (0.58) MAPTGAAALDH1A1KDM4ETNNI3
SCHEMBL2740986 0.76 MEN1 (0.56) MAPTGAAALDH1A1TDP1TNNI3
SCHEMBL2741006 0.76 MEN1 (0.55) MAPTGAAALDH1A1KDM4ETDP1
SCHEMBL2740985 0.76 MEN1 (0.54) MAPTGAAALDH1A1KDM4ETDP1
SCHEMBL2740993 0.76 MAPT (0.55) MAPTGAAALDH1A1KDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088772-B2 Sulfonamides and their use as a medicament THE GENETICS COMPANY, INC. (CH) 2012-01-03 — — US disclosed
US-8088772-B2 Sulfonamides and their use as a medicament THE GENETICS COMPANY, INC. (CH) 2012-01-03 — — US disclosed
US-20100249135-A1 SULFONAMIDES AND THEIR USE AS A MEDICAMENT THE GENETICS COMPANY, INC. (CH) 2010-09-30 — — US disclosed
US-20100249135-A1 SULFONAMIDES AND THEIR USE AS A MEDICAMENT THE GENETICS COMPANY, INC. (CH) 2010-09-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249135-A1 SULFONAMIDES AND THEIR USE AS A MEDICAMENT BCOR, CBR3, SULT1E1 MAPT 4202/4885GAA 4586/4885ALDH1A1 3484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback